Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355588 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL355152 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL13330197 | 0.86 | LMNA (0.39) | SMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL355211 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4ELMNACYP1A2 | |
| SCHEMBL353936 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4ELMNACYP1A2 | |
| SCHEMBL13330232 | 0.86 | LMNA (0.39) | SMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6009893 | 0.85 | HTT (0.43) | ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL353073 | 0.85 | GABBR2 (0.42) | SMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6009898 | 0.85 | HTT (0.43) | ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL6009922 | 0.85 | HTT (0.43) | ALDH1A1KDM4EPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | SMN1; SMN2 38/4885ALDH1A1 2230/4885KDM4E 4831/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 58/4885ALDH1A1 2989/4885KDM4E 4713/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SMN1; SMN2 77/4885ALDH1A1 3131/4885KDM4E 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.